Evidence map›Paper›PMID 36976236›Full record

ArticleMarine drugs2023

Fibrin and Marine-Derived Agaroses for the Generation of Human Bioartificial Tissues: An Ex Vivo and In Vivo Study.

Olimpia Ortiz-Arrabal, Ainhoa Irastorza-Lorenzo, Fernando Campos, Miguel Ángel Martín-Piedra, Víctor Carriel, Ingrid Garzón, Paula Ávila-Fernández, María José de Frutos, Emilio Esteban, Javier Fernández and 4 more

Open access · goldAbstract read
In one paragraph

Article in Marine drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Olimpia Ortiz-ArrabalTissue Engineering Group, Department of Histology, University of Granada and Instituto de Investigación Biosanitaria ibs.GRANADA, E18016 Granada, Spain.
Ainhoa Irastorza-LorenzoTissue Engineering Group, Department of Histology, University of Granada and Instituto de Investigación Biosanitaria ibs.GRANADA, E18016 Granada, Spain.
Fernando CamposTissue Engineering Group, Department of Histology, University of Granada and Instituto de Investigación Biosanitaria ibs.GRANADA, E18016 Granada, Spain.ORCID 0000-0003-0034-9264
Miguel Ángel Martín-PiedraTissue Engineering Group, Department of Histology, University of Granada and Instituto de Investigación Biosanitaria ibs.GRANADA, E18016 Granada, Spain.ORCID 0000-0002-4639-3175
Víctor CarrielTissue Engineering Group, Department of Histology, University of Granada and Instituto de Investigación Biosanitaria ibs.GRANADA, E18016 Granada, Spain.ORCID 0000-0002-8114-5644
Ingrid GarzónTissue Engineering Group, Department of Histology, University of Granada and Instituto de Investigación Biosanitaria ibs.GRANADA, E18016 Granada, Spain.
Paula Ávila-FernándezTissue Engineering Group, Department of Histology, University of Granada and Instituto de Investigación Biosanitaria ibs.GRANADA, E18016 Granada, Spain.
María José de FrutosHispanagar, SA, E09001 Burgos, Spain.
Emilio EstebanHispanagar, SA, E09001 Burgos, Spain.
Javier FernándezHispanagar, SA, E09001 Burgos, Spain.
Agustín JanerHispanagar, SA, E09001 Burgos, Spain.
Antonio CamposTissue Engineering Group, Department of Histology, University of Granada and Instituto de Investigación Biosanitaria ibs.GRANADA, E18016 Granada, Spain.
Jesús Chato-AstrainTissue Engineering Group, Department of Histology, University of Granada and Instituto de Investigación Biosanitaria ibs.GRANADA, E18016 Granada, Spain.ORCID 0000-0002-2378-2696
Miguel AlaminosTissue Engineering Group, Department of Histology, University of Granada and Instituto de Investigación Biosanitaria ibs.GRANADA, E18016 Granada, Spain.ORCID 0000-0003-4876-2672
Universidad de Granada · ES

Funding

Consejería de Salud y Familias, Junta de Andalucía, Spain PE-0395-2019 PI-0442-2019Hispanagar SA, Burgos, Spain, through CDTI, Ministry of Science and Innovation, Spain, Pro-grama Operativo Plurirregional de Crecimiento Inteligente (CRIN) IDI-20180052marco del Programa Operativo FEDER Andalucía 2014-2020, University of Granada and Conseje-ría de Transformación Económica, Industria, Conocimiento y Universidades B-CTS-504-UGR20 B-CTS-450-UGR20Spanish Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica (I+D+I) of the Spanish Ministry of Science and Innovation (Instituto de Salud Carlos III), FIS PI20/0317 FIS PI20/0318 FIS PI21/0980 ICI19/00024 ICI21/00010
6 · The paper itself

Abstract

Development of an ideal biomaterial for clinical use is one of the main objectives of current research in tissue engineering. Marine-origin polysaccharides, in particular agaroses, have been widely explored as scaffolds for tissue engineering. We previously developed a biomaterial based on a combination of agarose with fibrin, that was successfully translated to clinical practice. However, in search of novel biomaterials with improved physical and biological properties, we have now generated new fibrin-agarose (FA) biomaterials using 5 different types of agaroses at 4 different concentrations. First, we evaluated the cytotoxic effects and the biomechanical properties of these biomaterials. Then, each bioartificial tissue was grafted in vivo and histological, histochemical and immunohistochemical analyses were performed after 30 days. Ex vivo evaluation showed high biocompatibility and differences in their biomechanical properties. In vivo, FA tissues were biocompatible at the systemic and local levels, and histological analyses showed that biointegration was associated to a pro-regenerative process with M2-type CD206-positive macrophages. These results confirm the biocompatibility of FA biomaterials and support their clinical use for the generation of human tissues by tissue engineering, with the possibility of selecting specific agarose types and concentrations for applications requiring precise biomechanical properties and in vivo reabsorption times.

Indexed as

Biocompatible MaterialsFibrinHumansHydrogelsSepharoseTissue EngineeringTissue ScaffoldsBiocompatible MaterialsFibrinHydrogelsSepharoseagarosebiocompatibilitybiomaterialsfibrintissue engineering

Identifiers

PMID36976236
PMCPMC10058299
OpenAlexW4327975075

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.